Influence of blender type on the performance of ternary dry powder inhaler formulations
|
|
- Harry Harrison
- 5 years ago
- Views:
Transcription
1 Institute of Pharmacy Kiel University Influence of blender type on the performance of ternary dry powder inhaler formulations Mats Hertel
2 Theoretical background Binary formulation: 1 st blending Ternary formulation: 1 st blending 2 nd blending Advantages: Saturation of active sites Lucas P, et al. (1998) Buffer effects during blending Dickhoff BHJ, et al. (2006) Formation of agglomerates (fines + API) Louey MD, et al. (2002) Change in fluidisation behaviour Shur J, et al. (2008)
3 Theoretical background Blending process Blender type Blending time Blending speed Blending sequence Blending energy input Blending mechanism Drug deagglomeration Drug distribution on the carrier surface Press-on forces ontothe the carrier surface Mixture properties Drug content homogeneity Drug-carrier adhesion Drug aerosolisation behaviour adapted from W. Kaialy (2016)
4 How to find the right process parameters? Picomix high shear mixer module Rotation speed = min -1 Volume = 180 ml Turbula low shear tumble blender Rotation speed = min -1 Volume = 135 ml
5 Fine particle fraction [%] How to find the right process parameters? Methods: A Picomix and a Turbula mixer were used to prepare blends with salbutamol sulfate and a coarse lactose carrier Mixing time and mixing intensity were varied Blending energy input Picomix : 500 rpm Turbula : 90 rpm Cordts E, et al. (2012)
6 Used process parameters Preparation of model DPI formulations: Picomix high shear mixer module Rotation speed = 500 min -1 Blending time = 2-10 min Total rotations: Batch size = 30 g Effective volume = 24 % Turbula low shear tumble blender Rotation speed = 90 min -1 Blending time = min Total rotations: Batch size = 30 g Effective volume = 32 %
7 Materials Carrier (C) Lactose monohydrate (InhaLac 70) X 50 = ± 1.0 µm Share of blend = 91 % Fines (F) Lactose monohydrate (InhaLac 400) X 50 = 6.3 ± 0.0 µm Share of blend = 7.5 % API Budesonide X 50 = 1.5 ± 0.0 µm Share of blend = 1.5 %
8 Methods Factors: D-optimal quadratic setup Blender type: Turbula & Picomix Total rotations (Rot): 1000, 3000 & 5000 Blending order (BO): [C + F] + [API] & [C + API] + [F] Responses: Drug content homogeneity and recovery 10 samples, each 12 mg Determination of in vitro fine particle delivery (FPF, FPD, MMAD) 3 runs per blend; 5 shots per run +
9 Rel. standard deviation [%] Kiel University Recovery [%] Results Drug content homogeneity and recovery: Rotations Rotations Turbula Picomix Turbula Picomix error bars = min / max
10 Fine particle fraction [%] Results Determination of in vitro fine particle delivery (FPF, FPD, MMAD): Summary of fit (MLR) * Fine particle fraction R2R 2 Q2Q 2 RP p * The poor model validity is a result of an artificial lack of fit Coefficients plot (scaled and centered)
11 Results [Carrier + API] + [Fines] before dispersion [Carrier + API] + [Fines] after dispersion 100 µm 100 µm 20 µm 20 µm
12 1 st blending step Carrier + API Carrier + Fines Press-on forces Press-on forces Press-on forces Press-on forces
13 2 nd blending step [Carrier + API] + Fines [Carrier + Fines] + API Press-on forces Press-on forces Press-on forces Press-on forces
14 Inhalation [Carrier + API] + Fines [Carrier + Fines] + API FPF FPF
15 Conclusion How does blender type influence the performance of ternary dry powder inhaler formulations? No significant influence on blend homogeneity and API recovery The blender type had the lowest impact on the in vitro fine particle delivery How does blending process influence the performance of ternary dry powder inhaler formulations? The number of rotations was the most important factor influencing the FPF, due to an increase of press-on forces SEM pictures showed saturation of active sites and gave an explanation for blending order results
16 Thank you for your attention!
The influence of lactose particle size on dry powder inhalation performance
The influence of lactose particle size on dry powder inhalation performance MCC Starch Lactose Inhalation Superdisintegrants 1 Introduction In most dry powder inhalation (DPI) formulations carriers are
More informationContent Uniformity of Direct Compression tablets
Content Uniformity of Direct Compression tablets Contents 1 Summary 4 2 Introduction 4 3 The role of drug particle size 4 4 The role of mixing strategy 5 5 The role of excipients 5 6 Laboratory data 6
More informationTEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006.
(19) TEPZZ _784 A_T (11) EP 3 17 842 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 07.06.17 Bulletin 17/23 (1) Int Cl.: A61K 9/00 (06.01) A61K 31/439 (06.01) (21) Application number: 1197874.9
More informationInteractions, structure and process: relevant aspects of the development of lactose-based formulations and devices for dry powder inhalation
1 ORIGINAL TITLE Interactions, structure and process: relevant aspects of the development of lactose-based formulations and devices for dry powder inhalation PROPOSED TITLES Aspects of the development
More informationEverything for Inhalation
Everything for Inhalation Everything for Inhalation Inhalation drug product development at Hovione has a strong focus on formulation for Dry Powder Inhalers (DPI), particularly for capsule-based and reservoir-based
More informationINTEGRATED DESIGN SPACE TO DEVELOP BETTER DPI FORMULATIONS
INTEGRATED DESIGN SPACE TO DEVELOP BETTER DPI FORMULATIONS Here, Filipa Maia, PhD, and Maria Palha, MSc, both Scientists at Hovione, report a study whose objective was to establish relationships between
More informationResearch Paper. The Role of Fines in the Modification of the Fluidization and Dispersion Mechanism Within Dry Powder Inhaler Formulations
Pharmaceutical Research, Vol. 25, No. 7, July 2008 ( # 2008) DOI: 10.1007/s11095-008-9538-y Research Paper The Role of Fines in the Modification of the Fluidization and Dispersion Mechanism Within Dry
More informationEP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2008/29
(19) (12) EUROPEAN PATENT APPLICATION (11) EP 1 944 018 A1 (43) Date of publication: 16.07.2008 Bulletin 2008/29 (21) Application number: 07000425.4 (51) Int Cl.: A61K 9/14 (2006.01) A61K 31/4704 (2006.01)
More informationCOMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES
COMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES Miriam Sanz Cermeño and Helena Maria Cabral Marques UCTF, Faculdade de Farmácia, Universidade de Lisboa, PORTUGAL 1. Introduction Inhalation
More informationRespiratory. Martin Jetzer DDL27 Edinburgh December 2016
Respiratory Investigating the Effect of the Force Control Agent Magnesium Stearate in Fluticasone Propionate Dry Powder Inhaled Formulations with Single Particle Aerosol Mass Spectrometry Martin Jetzer
More informationDry Powder Inhaler. Developing an Efficient. 3M Conix DPI. White Paper / Spring Proven Solutions that Enable Your Success
3M Drug Delivery Systems Developing an Efficient Dry Powder Inhaler 3M Conix DPI White Paper / Spring 2011 Proven Solutions that Enable Your Success Introduction introduction Inhalation drug delivery has
More informationFigure 1: SEM Mannogem EZ (1000x)
Carrier-Mixing of Mannogem EZ with Micronized Low dose Furosemide: Uniformity of dosage unit study Sunil Kumar N *, John K Tillotson, Praveen Saligram, Robert Duffy SPI Pharma Inc. Introduction: To produce
More informationUniversity of Groningen. Optimisation of dry powder inhalation de Boer, Anne
University of Groningen Optimisation of dry powder inhalation de Boer, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationResearch Article. *Corresponding author Mahesh M.Giri
Scholars Academic Journal of Pharmacy (SAJP) ISSN 2320-4206 Sch. Acad. J. Pharm., 2013; 2(3):260-267 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationFormulation Considerations for Inhaled Products
Formulation Considerations for Inhaled Products Formulation Considerations of Inhaled Products Inhalation Therapy Nebulizers and Formulations Dry Powder Inhalers and Formulations Metered Dose Inhalers
More informationUniversity of Groningen. Adhesive mixtures for powder inhalation Dickhoff, Bastiaan Hendrikus Jozef
University of Groningen Adhesive mixtures for powder inhalation Dickhoff, Bastiaan Hendrikus Jozef IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationPrimellose is an excellent choice as superdisintegrant in ODT applications
Primellose is an excellent choice as superdisintegrant in ODT applications MCC Starch Lactose Inhalation Superdisintegrants Summary In orally disintegrating tablets, the excipients of choice in direct
More informationUniversity of Groningen. Optimisation of dry powder inhalation Boer, Anne Haaije de
University of Groningen Optimisation of dry powder inhalation Boer, Anne Haaije de IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationRDD Europe 2009 Workshop
RDD Europe 2009 Workshop 20 May 2009, Lisbon, Portugal This file is a redacted version of the presentation used during the Workshop and is suitable for electronic distribution. An Introduction to Differentiating
More informationLubriTose Mannitol Michael Crowley, Director of R&D, Excipients
LubriTose Mannitol Michael Crowley, Director of R&D, Excipients Introduction Michael Crowley Director of R&D Excipients 158 St. Highway 320 Norwich, NY 13815 PH 315-802-5970 Michael.Crowley@Kerry.com 2
More informationRDD Europe 2011 Workshop 4 May 2011
RDD Europe 2011 Workshop 4 May 2011 This file represents the slides presented on May 4, 2011 by 3M Drug Delivery Systems at the RDD Europe 2011 Conference in Berlin, Germany. Slides have been modified
More informationPARTICLE-PARTICLE INTERACTIONS BETWEEN TAILORED MANNITOL CARRIER PARTICLES AND DRUG PARTICLES FOR INHALATION
PARTICLE-PARTICLE INTERACTIONS BETWEEN TAILORED MANNITOL CARRIER PARTICLES AND DRUG PARTICLES FOR INHALATION DOCTORAL THESIS SUBMITTED IN THE FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR IN
More informationNovel Application of an Old Excipient L-Leucine- Improving Physical and. Aerosolization Stability of Spray Dried Amorphous DPI Formulations.
1 Novel Application of an Old Excipient L-Leucine- Improving Physical and Aerosolization Stability of Spray Dried Amorphous DPI Formulations. Nivedita Shetty 1, Dmitry Zemlyanov 2, Qi (Tony) Zhou 1 1 Department
More informationCase Study 1: Pharmaceutical Development of EXUBERA
Case Study 1: Pharmaceutical Development of EXUBERA Nancy Harper, PhD Research Fellow, Parenteral Development Center of Emphasis Pfizer Global R&D IPAC-RS Conference November 2006 1 EXUBERA Insulin human
More informationReceived: ; Revised; Accepted: PROCESS VALIDATION OF FORMOTEROL FUMARATE AND BUDESONIDE DRY POWDER INHALATION
International Journal of Institutional Pharmacy and Life Sciences 2(5): September-October 2012 INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES Pharmaceutical Sciences Original Article!!!
More informationThe Kinetics of De-agglomeration of Magnesium Stearate Dry-Coated Salbutamol Sulphate Powders
KONA Powder and Particle Journal No. 32 (2015) 131 142/Doi:10.14356/kona.2015001 Original Research Paper The Kinetics of De-agglomeration of Magnesium Stearate Dry-Coated Salbutamol Sulphate Powders Jiani
More informationAssessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy
Starch 1500 Application Data Partially Pregelatinized Maize Starch Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy OBJECTIVE To characterize
More informationInnovation in formulations to improve aerosol delivery
Innovation in formulations to improve aerosol delivery Peter York Chief Scientist, CrystecPharma DDL Conference Edinburgh, 7-9 th December 2016 Triumvirate in design of inhalation medicines Nebulisers,
More informationTechnical brochure InhaLac
N A DRY POWDER INHALATION SIEVED/MILLED/MICRONIZED LACTOSE AC Technical brochure MEGGLE s, milled and alpha-lactose monyhydrate for dry powder : General information The delivery of active pharmaceutical
More informationCAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES
xxx Qualicaps CAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES There is a wide range of devices available to deliver inhalation therapies, but there is increasing
More informationCitation for published version (APA): Westerman, E. M. (2009). Studies on antibiotic aerosols for inhalation in cystic fibrosis s.n.
University of Groningen Studies on antibiotic aerosols for inhalation in cystic fibrosis Westerman, Elisabeth Mechteld IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)
More informationTeerapol SRICHANA,*,a Anthony BRAIN, b Christopher MARRIOTT, c and Gary Peter MARTIN c
February 2000 Chem. Pharm. Bull. 48(2) 167 174 (2000) 167 A Study of Drug Carrier Interactions in Dry Powder Inhaler Formulations Using the Andersen Cascade Impactor, X-Ray Microanalysis and Time of Flight
More informationReal Time and In Situ Monitoring of the Crystallization of Palm Oil-based Products using Focused Beam Reflectance Measurement (FBRM)
Real Time and In Situ Monitoring of the Crystallization of Palm Oil-based Products using Focused Beam Reflectance Measurement (FBRM) Elina Hishamuddin Malaysian Palm Oil Board, Malaysia OVERVIEW Introduction
More informationUse of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung
Use of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung Nia Stevens 9 th November 2016 Thanks to Richard Kaye, James Mitchell, Dave Prime at GSK Bahman Asgharian and Owen
More informationUniversity of Groningen. Adhesive mixtures for powder inhalation Dickhoff, Bastiaan Hendrikus Jozef
University of Groningen Adhesive mixtures for powder inhalation Dickhoff, Bastiaan Hendrikus Jozef IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationFACTORIAL STUDIES ON THE EFFECTS OF HYDROXY PROPYL β- CYCLODEXTRIN AND POLOXAMER 407 ON THE SOLUBILITY AND DISSOLUTION RATE OF BCS CLASS II DRUGS
JChrDD Vol 2 Issue 2 2011: 89-93 ISSN 2249-6785 Journal of Chronotherapy and Drug Delivery Received: August 06, 2011 Accepted: Sep 12, 2011 Original Research Paper FACTORIAL STUDIES ON THE EFFECTS OF HYDROXY
More informationUniversity of Groningen. Optimisation of dry powder inhalation de Boer, Anne
University of Groningen Optimisation of dry powder inhalation de Boer, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationImproved Aerosol Deposition Profiles from Dry Powder Inhalers
1 University of Hertfordhire Improved Aerosol Deposition Profiles from Dry Powder Inhalers Submitted to the University of Hertfordshire in partial fulfilment of the requirements of the degree of Doctor
More informationA Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data
A Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data IPAC-RS/UF Orlando Inhalation Conference March 18-20, 2014 Dennis Sandell, S5 Consulting Contents The data brief
More informationChemate and Chowdary, IJPSR, 2012; Vol. 3(7): ISSN:
IJPSR (2012), Vol. 3, Issue 07 (Research Article) Received on 18 March, 2012; received in revised form 25 April, 2012; accepted 22 June, 2012 A FACTORIAL STUDY ON ENHANCEMENT OF SOLUBILITY AND DISSOLUTION
More informationInfluence of Batch Cooling Crystallization on Mannitol Physical Properties and Drug Dispersion from Dry Powder Inhalers
pubs.acs.org/crystal Influence of Batch Cooling Crystallization on Mannitol Physical Properties and Drug Dispersion from Dry Powder Inhalers Waseem Kaialy,*,, Hassan Larhrib, Martyn Ticehurst, and Ali
More informationThe use of a novel optical technology, the VariDose, was also investigated in order to obtain a system which can lead to an effective and efficient
Acknowledgments I would like to express my deepest gratitude to my supervisor Dr Robert Price for his guidance, enthusiasm, support and encouragement throughout the course of my research. My sincere thanks
More informationOCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100
IC OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE AC Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture
More informationNovel drug delivery system. Nanos-in-Micros
Novel drug delivery system Nanos-in-Micros Janne Raula The annual symposium of the Finnish Society of Physical Pharmacy February 9 th, 2012 Medicinal treatment Indications -Neurosurgery -General surgery
More informationAvailable online Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 26, 8(2):7-7 Research Article ISSN : 975-7384 CODEN(USA) : JCPRC5 Optimization of directly compressible mixtures of microcrystalline
More informationIntroduction. Carlos Molina 1 & Waseem Kaialy 2 & Qiao Chen 1 & Daniel Commandeur 1 & Ali Nokhodchi 1,3
Drug Delivery and Translational Research https://doi.org/10.1007/s13346-017-0462-8 ORIGINAL ARTICLE Agglomerated novel spray-dried lactose-leucine tailored as a carrier to enhance the aerosolization performance
More informationSUGGESTED FORMULATION. Lot Number. Expiry Date. Ingredient Listing Qty. Unit NDC # Supplier
9/17/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Aloe Vera (Powder) (Freeze Dried) 0.200 g Tacrolimus 5% Stock Powder Blend 0.600 g Ethoxy Diglycol 1.0 ml Medisca U-Mild
More informationOPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER
OPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER US FDA guidance for the in vitro demonstration of bioequivalence in a generic nebuliser directly references
More informationLactose Engineering for Better Performance in Dry Powder Inhalers
Advanced Pharmaceutical Bulletin, 2012, 2(2), 183-187 doi: 10.5681/apb.2012.028 http://apb.tbzmed.ac.ir/ Lactose Engineering for Better Performance in Dry Powder Inhalers Yahya Rahimpour 1, Hamed Hamishehkar
More informationGranulation Aggregation
Granulation Aggregation Wet granulation Solvent granulation (crust granules) Binder granulation (sticked granules) Granulation liquid Water Water + alcohol mixture Macromolecular colloidal solution i.e.:
More informationskim milk as carrier by kneading method. They were evaluated for percentage yield, drug content, FT-IR
Available Online through ISSN: 0975-766X CODEN: IJPTFI Research Article www.ijptonline.com ENHANCEMENT OF SOLUBILITY & DISSOLUTION RATE OF LAMOTRIGINE BY KNEADING METHOD Gadhave M.V*, Mahakal A. J., Gaikwad
More informationPharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency
Pharma & Food Solutions POLYOX TM Water Soluble Resins Combining Flexibility with Consistency POLYOX 9-13 POLYOX 9-13 POLYOX * are nonionic poly (ethylene oxide) polymers that meet all the specifications
More informationIngredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose
1 Pharmaceutical industry borrowed ingredients from other industries Food Cosmetic Industrial Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work that has all changed
More informationThe influence of relative humidity on the carrier particle surface characteristics used in dry powder inhalation formulation
Libyan Journal of Science & Technology 7:1 (2018) 44 53 The influence of relative humidity on the carrier particle surface characteristics used in dry powder inhalation formulation Antesar. M. Boshhiha
More informationLecipro AOCS Lecithin SC Montreal
Lecithin Dispersion and Emulsification Demo W. van Nieuwenhuyzen Lecipro Consulting www.lecipro.nl AOCS Lecithin SC - Montreal, April 27-28, 28, 2013 Lecipro AOCS Lecithin SC Montreal 2013 1 Topics Emulsifying
More informationEffects of Surface Processing of Lactose Carrier Particles on Dry Powder Inhalation Properties of Salbutamol Sulfate
938 Chem. Pharm. Bull. 52(8) 938 942 (2004) Vol. 52, No. 8 Effects of Surface Processing of Lactose Carrier Particles on Dry Powder Inhalation Properties of Salbutamol Sulfate Kotaro IIDA,*,a Yukari INAGAKI,
More informationResearch Article. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products
The AAPS Journal, Vol. 17, No. 6, November 2015 ( # 2015) DOI: 10.1208/s12248-015-9802-0 Research Article De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in
More informationSTARCH Application Data
STARCH 1500 Application Data Partially Pregelatinized Maize Starch Starch 1500, Partially Pregelatinized Maize Starch, Used as a Binder Disintegrant in High Shear Wet Granulation Comparison to Povidone
More informationIdentification of crystalline forms suitable for inhalation in drug discovery
Identification of crystalline forms suitable for inhalation in drug discovery Valentina Diana Di Lallo Chiesi Farmaceutici - Corporate R&D Preclinical Analytics & Early Formulations Department Crystallization:
More informationSummary. Introduction. Procedures. Swine Day 1998 EFFECTS OF PARTICLE SIZE AND MIXING TIME ON UNIFORMITY AND SEGREGATION IN PIG DIETS
Swine Day 1998 EFFECTS OF PARTICLE SIZE AND MIXING TIME ON UNIFORMITY AND SEGREGATION IN PIG DIETS N. Amornthewaphat 1, K. C Behnke', and J. D. Hancock Summary Diet uniformity, as represented by the coefficient
More informationProf. Dr. Henderik W. Frijlink
Pulmonary drug administration technologies to improve the therapy in Asthma, COPD and beyond. Prof. Dr. Henderik W. Frijlink Department of Pharmaceutical Technology and Biopharmacy University of Groningen
More informationExcipient Considerations for Continuous Manufacturing Implementation
Excipient Considerations for Continuous Manufacturing Implementation FDA-PQRI Conference March 22-24, 2017 David R. Schoneker Director of Global Regulatory Affairs Email: dschoneker@colorcon.com 1 Continuous
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationPreparation of Microparticles Containing Rifampicin as Dry Powder Formulation: In Vitro Studies on Aerosol Performance
RESEARCH ARTICLE Am. J. PharmTech Res. 2012; 2(4) ISSN: 2249-3387 Preparation of Microparticles Containing Rifampicin as Dry Powder Formulation: In Vitro Studies on Aerosol Performance Aliasgar J. Kundawala.
More informationProceeding of ICNM st International Conference on Nanostructured Materials and Nanocomposites (6 8 April 2009, Kottayam, India)
Proceeding of ICNM - 2009 1 st International Conference on Nanostructured Materials and Nanocomposites (6 8 April 2009, Kottayam, India) Published by : Applied Science Innovations Private Limited, India.
More informationA Comparison of Aerosol Performance Using Standardized Entrainment Tubes vs. Dry Powder Inhaler Devices
A Comparison of Aerosol Performance Using Standardized Entrainment Tubes vs. Dry Powder Inhaler Devices Zhen Xu 1 and Anthony J Hickey 2 1 Division of Molecular Pharmaceutics, Eshelman School of Pharmacy,
More informationPerformance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI
3M Drug Delivery Systems Performance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI Poster Reprint / Spring 2011 John Simons 1, Herbert Chiou 1, Louis Sigtermans 1, Tom Robison 1, Debra
More informationTable 1. Coating Parameters
ACRYL-EZE Aqueous Acrylic Enteric System Application Data Performance Characteristics of Acryl-EZE, Aqueous Acrylic Enteric System Eudragit L1-55 is a copolymer of methacrylic acid and ethyl acrylate (1:1
More informationResearch Article Formulation and Evaluation of Combination Dry Powder for Inhalation: Influence of Crystalline Excipient
Research Article Formulation and Evaluation of Combination Dry Powder for Inhalation: Influence of Crystalline Excipient Shah Vishal Vilas*, Shah Nutan Dhanpal and Patil Smita Jagganath Appasaheb Birnale
More informationContinuous Granulation Using a Twin-Screw Extruder. Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016
Continuous Granulation Using a Twin-Screw Extruder Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016 What is a twin screw extruder and how to use it for continuous granulation? Dry feed:
More informationLABORATORY MANUAL PHM 2143 PHYSICAL PHARMACY II
DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY LABORATORY MANUAL PHM 2143 PHYSICAL PHARMACY II NAME MATRIC NO. Please read the instructions, carry out the lab practical and answer the questions. You may be requested
More informationIngredient Listing Qty. Unit NDC # Supplier g. Sterile Preparation
Note: Glucosamine Sulfate Potassium Chloride 1267 mg is equivalent to Glucosamine 750 mg. 11/8/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Chondroitin Sulfate Sodium,
More informationDevice Design Similarity
Device Design Similarity Dave Parkins Director DPI Product Development PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products. Bethesda March 9-10, 2009 Device Similarity
More informationRe-compaction properties of lactose and microcrystalline cellulose
Re-compaction properties of lactose and microcrystalline cellulose Individual excipients MCC Starch Lactose Inhalation Superdisintegrants SuperTab 21AN (anhydrous lactose) is the preferred form of lactose
More informationThe effect of different coating materials on the prevention of powder bounce in the next generation impactor
Research in Pharmaceutical Sciences, June 2018; 13(3): 283-287 Received: June 2017 Accepted: December 2017 School of Pharmacy & Pharmaceutical Sciences Isfahan University of Medical Sciences Short Communication
More informationA FACTORIAL STUDY ON ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF IBUPROFEN BY β CYCLODEXTRIN AND SOLUTOL HS15
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article A FACTORIAL STUDY ON ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF IBUPROFEN BY β CYCLODEXTRIN
More informationENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF NIMESULIDE BY CYCLODEXTRINS, POLOXAMER AND PVP
Int. J. Chem. Sci.: 9(2), 20, 637-646 ISSN 0972-768X www.sadgurupublications.com ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF NIMESULIDE BY CYCLODEXTRINS, POLOXAMER AND PVP K. P. R. CHOWDARY *, K.
More informationPreparation of Ultra-fine Salbutamol Sulfate Particles by Reactive Precipitation and Characterization of Dry Powder Inhalant *
Chinese Journal of Chemical Engineering, 16(5) 791 795 (2008) Preparation of Ultra-fine Salbutamol Sulfate Particles by Reactive Precipitation and Characterization of Dry Powder Inhalant * XU Jing ( 续京
More informationINVESTIGATION OF ELECTROSTATIC CHARGING PHENOMENA IN DRY POWDER INHALERS AND THE EFFECT ON DEPOSITION. Martin Jan Telko
INVESTIGATION OF ELECTROSTATIC CHARGING PHENOMENA IN DRY POWDER INHALERS AND THE EFFECT ON DEPOSITION Martin Jan Telko A dissertation submitted to the faculty of the University of North Carolina at Chapel
More informationIMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING
IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING In this piece, Mark Copley, Sales Director of Copley Scientific, provides some background on mouth-throat models for
More informationProcess Drift and it s Resolution in the Manufacture of Drug Products. MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations
Process Drift and it s Resolution in the Manufacture of Drug Products MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations Ed Warner, Merck MMD December 2, 2010 PQRI-FDA Workshop on Process
More informationIs there a Sticky Sweet Spot?
Is there a Sticky Sweet Spot? Mixture Design of a Pressure Sensitive Adhesive Emulsion Formulation M. Michaelis, C. S. Leopold Department of Chemistry Division of Pharmaceutical Technology University of
More informationA FACTORIAL STUDY ON THE ENHANCEMENT OF DISSOLUTION RATE OF KETOPROFEN BY SOLID DISPERSION IN COMBINED CARRIERS
Research Article A FACTORIAL STUDY ON THE ENHANCEMENT OF DISSOLUTION RATE OF KETOPROFEN BY SOLID DISPERSION IN COMBINED CARRIERS K. P. R. Chowdary *, Tanniru Adinarayana, T. Vijay, Mercy. R. Prabhakhar
More informationSYNTHETIC WAXES NATURAL WAXES HYBRID WAXES
SYNTHETIC WAXES NATURAL WAXES HYBRID WAXES HYBRID WAXES AIR CLASSIFICATION PROCESS DEUREX AIR CLASSIFICATION PROCESS Waxes are classified by air stream Wide range of delivery forms from fine granules through
More informationMorphological modification of starch - New separating and carrier materials
57. Starch Convention, Detmold, 26.-28.04.2006 Morphological modification of starch - New separating and carrier materials B. Volkert, C. Fanter, W. Wagenknecht, R. Leibnitz Content 1. Initial situation
More informationThe effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts.
The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. Ali Nokhodchi Department of Pharmacy, School of Health and Life
More informationFORMULATION AND CHARACTERIZATION OF TELMISATAN SOLID DISPERSIONS
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 974-434 Vol.2, No.1, pp 341-347, Jan-Mar 1 FORMULATION AND CHARACTERIZATION OF TELMISATAN SOLID DISPERSIONS Kothawade S. N. 1 *, Kadam
More informationUniversity of Groningen. Optimisation of dry powder inhalation de Boer, Anne
University of Groningen Optimisation of dry powder inhalation de Boer, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationMicroNIR: soluzioni QbD e PAT
MicroNIR: soluzioni QbD e PAT Milano, 8 Maggio 2018 Emiliano Genorini MicroNIR EMEA & India Account Manager +39 039 9300225 (office) +39 337 1362987 (mobile) Via Torri Bianche, 10 20871, Vimercate (MB)
More informationApplication Note 201
201 Application note: Determination of the of Milk Application note no.: 201 By: E. de Jong Date: January 2001 Copyright Delta Instruments 2005 www.deltainstruments.com Table of contents Table of contents
More informationSpray-Drying Formulation + Process Development Advances
Spray-Drying Formulation + Process Development Advances Expand Opportunities for Formulations Via Intranasal and Pulmonary Delivery authors Jeff Breit, Ph.D. Frederique Bordes-Picard Dominique Cade, Ph.D.
More informationPREPARATION AND AEROSOLIZATION STUDIES OF FINE POWDERS COMPOSED OF POORLY SOLUBLE DRUGS FOR PULMONARY DRUG DELIVERY
AMANDA ATTOBRAH PREPARATION AND AEROSOLIZATION STUDIES OF FINE POWDERS COMPOSED OF POORLY SOLUBLE DRUGS FOR PULMONARY DRUG DELIVERY Master of Science Thesis EXAMINERS: Professor Mika Valden, Dr. Janne
More informationInvestigation of High Shear Wet Granulation Processes Using Different Parameters and Formulations
22 Chem. Pharm. Bull. 56(1) 22 27 (2008) Vol. 56, No. 1 Investigation of High Shear Wet Granulation Processes Using Different Parameters and Formulations Siling WANG, a Guanhao YE,*,a Paul Wan Sia HENG,
More informationThe pulmonary route is gaining increasing
ELECTRONICALLY REPRINTED FROM FEBRUARY 2014 Pulmonary Drug Delivery Particle Engineering for Inhaled Therapeutics Moderated by Adeline Siew, PhD Industry experts discuss the various factors affecting drug
More informationInhalation Product Research at FDA
Inhalation Product Research at FDA Changning Guo Ph. D., Chemist Division of Pharmaceutical Analysis FDA/CDER/OPS/OTR 2016 GPhA CMC workshop, May 17, 2016 Disclaimer: This presentation reflects the views
More informationSELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS
SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Poonam Sheth, PharmD, PhD, Research Scientist, Inhalation Matthew T. Marmura, Research Scientist, Inhalation Recipharm is frequently asked to help
More informationBeclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults
CLENIL MODULITE Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults Corticosteroids for the treatment of chronic asthma in adults and children aged 12
More informationRespiratory Therapy. Medical/Scientific/General Background
Respiratory Therapy Medical/Scientific/General Background Marketing Europe Dr. Rainer Jakobs PMM Europe 1 Dr. Rainer Jakobs, PMM Europe RT Medical/Scientific/General Background 2 Dr. Rainer Jakobs, PMM
More informationVI-RDX FROM LAB TO PILOT SCALE
VI-RDX FROM LAB TO PILOT SCALE G. ECK, M. FOURDINIER (a) L. BORNE, F. SCHLESSER, D. STEHLIN (b) (a) EURENCO (b) French-German Research Institute of Saint Louis Introduction VI-RDX at lab scale Scale up
More information